Back to Sectors

BBNX

Beta Bionics, Inc.
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Signal Magnitude Chart

NEUTRAL | 30% | 5/22/2026 | management changeNEUTRAL | 20% | 5/22/2026 | regulatory actionNEUTRAL | 30% | 5/22/2026 | management changeNEUTRAL | 20% | 5/22/2026 | regulatory actionNEUTRAL | 30% | 5/22/2026 | management changeNEUTRAL | 20% | 5/22/2026 | regulatory actionNEUTRAL | 30% | 5/22/2026 | management changeNEUTRAL | 20% | 5/22/2026 | regulatory actionNEUTRAL | 30% | 5/22/2026 | management changeNEUTRAL | 20% | 5/22/2026 | regulatory actionNEUTRAL | 30% | 5/22/2026 | management changeNEUTRAL | 20% | 5/22/2026 | regulatory actionNEUTRAL | 30% | 5/22/2026 | management changeNEUTRAL | 20% | 5/22/2026 | regulatory actionMay 26May 26HIGHLOW
bullish
bearish
neutral

Signal Timeline

neutralMay 22

Election of Class I directors completed as part of the annual meeting cycle.

management change
30%
neutralMay 22

Governance stability maintained ahead of anticipated regulatory milestones.

regulatory action
20%
neutralMay 22

Election of Class I directors completed as part of the annual meeting cycle.

management change
30%
neutralMay 22

Governance stability maintained ahead of anticipated regulatory milestones.

regulatory action
20%
neutralMay 22

Election of Class I directors completed as part of the annual meeting cycle.

management change
30%
neutralMay 22

Governance stability maintained ahead of anticipated regulatory milestones.

regulatory action
20%
neutralMay 22

Election of Class I directors completed as part of the annual meeting cycle.

management change
30%
neutralMay 22

Governance stability maintained ahead of anticipated regulatory milestones.

regulatory action
20%
neutralMay 22

Election of Class I directors completed as part of the annual meeting cycle.

management change
30%
neutralMay 22

Governance stability maintained ahead of anticipated regulatory milestones.

regulatory action
20%
neutralMay 22

Election of Class I directors completed as part of the annual meeting cycle.

management change
30%
neutralMay 22

Governance stability maintained ahead of anticipated regulatory milestones.

regulatory action
20%
neutralMay 22

Election of Class I directors completed as part of the annual meeting cycle.

management change
30%
neutralMay 22

Governance stability maintained ahead of anticipated regulatory milestones.

regulatory action
20%

Filing History

8-KMay 22, 2026

The 8-K filing confirms the successful completion of the 2026 Annual Meeting, providing the necessary legal and administrative stability for Beta Bionics to continue operations. While the bull case views this as a green light for aggressive expansion, the bear case interprets the specific voting patterns as a warning sign of investor dissatisfaction. Ultimately, the impact of this filing is neutral to slightly positive, as it maintains the status quo of leadership while the market awaits more substantive catalysts regarding FDA decisions and revenue growth.